ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 570,20
-0,77%
Dow Jones
38 834,86
0,15%
DAX
18 067,91
-0,31%
Brent Oil
84,555
-0,17%
Bitcoin
65 086,43
0,18%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Nautilus Biotechnology Inc (NAUT)

  7. Nautilus Biotechnology Inc (NAUT) Actualités

NAUT Nautilus Biotechnology Inc

2,43
-0,13 (-5,08%)
19 Juin 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Nautilus Biotechnology Inc NAUT NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-0,13 -5,08% 2,43 06:00:05
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
2,59 2,41 2,615 2,41 2,56
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
17/6/202423:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/6/202422:25EDGAR2Form 8-K - Current report
23/5/202414:00GLOBENautilus Biotechnology to Participate in the Goldman Sachs..
30/4/202414:00GLOBENautilus Biotechnology Reports First Quarter 2024 Financial..
11/4/202414:00GLOBENautilus Biotechnology to Announce First Quarter 2024..
07/3/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
06/3/202422:39EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
05/3/202422:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202422:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202422:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202422:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/2/202414:00GLOBENautilus Biotechnology Reports Fourth Quarter and Fiscal..
28/2/202413:26EDGAR2Form 8-K - Current report
28/2/202413:25EDGAR2Form S-3 - Registration statement under Securities Act of..
28/2/202413:15EDGAR2Form S-8 - Securities to be offered to employees in employee..
28/2/202413:04EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
28/2/202413:03EDGAR2Form 8-K - Current report
22/2/202414:00GLOBENautilus Biotechnology to Participate in the TD Cowen 44ᵗʰ..
07/2/202414:00GLOBENautilus Biotechnology to Announce Fourth Quarter and Full..
14/12/202322:17EDGAR2Form 8-K - Current report
30/11/202314:00GLOBENautilus Biotechnology Co-founder and Chief Scientist Parag..
01/11/202313:05GLOBENautilus Biotechnology Appoints Martin Huber, Ph.D., as Vice..
31/10/202321:02EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
31/10/202313:05GLOBENautilus Biotechnology Reports Third Quarter 2023 Financial..
11/10/202314:05GLOBENautilus Biotechnology to Announce Third Quarter Financial..
06/9/202313:30GLOBENautilus Biotechnology to Participate in Upcoming September..
04/8/202314:00GLOBENautilus Biotechnology to Participate in Upcoming August..
02/8/202322:03EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
02/8/202313:30GLOBENautilus Biotechnology Reports Second Quarter 2023 Financial..
11/7/202315:23GLOBENautilus Biotechnology to Announce Second Quarter Financial..

Dernières Valeurs Consultées

NASDAQ
NAUT
Nautilus Biotechnology
HITB
WLDUSDT
Worldcoin
LSE
52IP
Aviva 23
AMEX
FIGY
BIT
P1VA39
NLBNPIT1VA39 20351221 21...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés